Boston, MA 03/28/2014 (wallstreetpr) – Mandalay Digital Group Inc (NASDAQ:MNDL), a provider of mobile and wireless content sharing solution for operators, had its stock price adjusted at Merriman Capital Inc. The analysts at the brokerage assigned price target of $10 on the stock, up from $8.5 in the previous view. This upgrade note issued Thursday, came on the back of stock selling at MNDL. In a Securities Exchange Commission filing, the company disclosed that its majority shareholder unloaded about $122,000 shares. Trinad Capital Master Fund Ltd sold the shares at the average price of $4.10, thus fetching roughly $0.5 million. The shareholder owns more than 10 percent stake in the company. Shares of Mandalay Digital Group Inc (NASDAQ:MNDL) closed the previous session up more than 8 percent but standing below the price at which the majority shareholder sold the stock.
The grocery retailer Roundy’s Inc (NYSE:RNDY) is promising to turnaround and provide positive results to shareholders. The company is repositioning itself by weighing in on operating expenses and costs while expand the market for better sales. And on this note, analysts at Bank of America Corp (NYSE:BAC) agree. The analysts event went ahead to consider a buy recommendation in the stock while modeling a premium price target at $8. Shares soared in the previous session. While BAC is bullish in the stock of RNDY, it is not the same story at TheStreet where the stock is recommended for sell. TheStreet cites, among other weaknesses, poor cash flow and weak profit margins, all of which don’t sit well for Roundy’s Inc (NYSE:RNDY)’s short-term.
Insmed Incorporated (NASDAQ:INSM)’s experimental drug Arkayce, which is fronted for treatment of lung infection caused by bacteria failed to meet the trail objective in the primary test. This caused lack of peace among investors during yesterday’s session. However, things were corrected when analysts sought to set records straight that regardless of Arkayce failing to show positive signs in patients during primary test, there was another chance for the drug. Analysts cited that the drug still had secondary data to provide, which are of more relevance even to the regulators – Food and Drug Administration.
